AI Engines For more Details: Perplexity Kagi Labs You
Antineoplastic Activity: Floxuridine belongs to the class of medications known as antimetabolites. It works by interfering with the synthesis of DNA and RNA, which are essential for the growth and replication of cancer cells. By inhibiting nucleic acid synthesis, floxuridine prevents cancer cells from proliferating and induces their death.
Treatment of Colorectal Cancer: Floxuridine is commonly used in the treatment of colorectal cancer, particularly when the cancer has spread to the liver (metastatic colorectal cancer). It may be administered directly into the hepatic artery (intra-arterial infusion) to target tumors in the liver.
Administration Route: Floxuridine is typically administered as an intravenous infusion or through direct injection into the hepatic artery. In the case of hepatic artery infusion, floxuridine is delivered directly to the liver, allowing for higher concentrations of the drug to reach the tumor while minimizing systemic side effects.
Adverse Effects: Common side effects of floxuridine may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and mucositis (inflammation of the mucous membranes). Bone marrow suppression, resulting in decreased production of blood cells (myelosuppression), may also occur, leading to anemia, leukopenia, and thrombocytopenia.
Liver Toxicity: Floxuridine can cause hepatotoxicity (liver damage), particularly when administered via hepatic artery infusion. Hepatic artery occlusion or liver dysfunction may occur as a result of the infusion procedure, necessitating close monitoring of liver function during treatment.
Hand-Foot Syndrome: Floxuridine may cause a side effect known as hand-foot syndrome (palmar-plantar erythrodysesthesia), characterized by redness, swelling, and pain in the palms of the hands and soles of the feet. This condition can be dose-limiting and may require dose adjustments or discontinuation of treatment.
Bone Marrow Suppression: Floxuridine can suppress bone marrow function, leading to a decreased production of white blood cells, red blood cells, and platelets. This can increase the risk of infections, anemia, and bleeding, necessitating regular monitoring of blood cell counts during treatment.
Contraindications and Precautions: Floxuridine is contraindicated in individuals with known hypersensitivity to the drug or its components. It should be used with caution in patients with preexisting liver disease or impaired bone marrow function. Pregnancy and breastfeeding are generally contraindicated due to the potential risk of harm to the fetus or infant.
Monitoring and Supportive Care: Patients receiving floxuridine therapy require close monitoring of liver function, blood cell counts, and renal function. Supportive care measures, such as antiemetic medications to manage nausea and vomiting, may be prescribed to improve tolerance to treatment.
Combination Therapy: Floxuridine may be used in combination with other chemotherapy drugs or radiation therapy as part of a multidisciplinary approach to cancer treatment. The choice of treatment regimen depends on factors such as the type and stage of cancer, as well as the patient's overall health and treatment goals.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Escherichia | genus | Decreases |
0 | 2 | Streptococcus | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Streptococcus suis | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
0 | 1 | Streptococcus suis GZ1 | strain | Decreases |
0 | 1 | Streptococcus suis 6407 | strain | Decreases |
0 | 1 | Streptococcus suis 98HAH33 | strain | Decreases |
0 | 1 | Streptococcus suis D12 | strain | Decreases |
0 | 1 | Streptococcus suis BM407 | strain | Decreases |
0 | 1 | Streptococcus suis T15 | strain | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
Acne | 0.6 | 0.6 | |
ADHD | 3.3 | 0.6 | 4.5 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
Allergic Rhinitis (Hay Fever) | 2.4 | 1.5 | 0.6 |
Allergies | 3.6 | 1.4 | 1.57 |
Allergy to milk products | 1.7 | 1.3 | 0.31 |
Alopecia (Hair Loss) | 0.6 | 0.6 | |
Alzheimer's disease | 4.2 | 5.1 | -0.21 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.9 | 1 |
Ankylosing spondylitis | 3 | 1.2 | 1.5 |
Anorexia Nervosa | 1.2 | 2.8 | -1.33 |
Antiphospholipid syndrome (APS) | 1.5 | 1.5 | |
Asthma | 4 | 1.1 | 2.64 |
Atherosclerosis | 1.8 | 1.9 | -0.06 |
Atrial fibrillation | 2.5 | 2.1 | 0.19 |
Autism | 7.7 | 6.4 | 0.2 |
Autoimmune Disease | 0.9 | 0.7 | 0.29 |
Barrett esophagus cancer | 0.3 | -0.3 | |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 2.1 | 2.1 | |
Bipolar Disorder | 2.1 | 1.4 | 0.5 |
Brain Trauma | 0.3 | 1.1 | -2.67 |
Breast Cancer | 0.9 | 0.3 | 2 |
Cancer (General) | 0.3 | 1.8 | -5 |
Carcinoma | 2.5 | 1.3 | 0.92 |
Celiac Disease | 2.7 | 1.3 | 1.08 |
Cerebral Palsy | 0.8 | 1.1 | -0.38 |
Chronic Fatigue Syndrome | 5 | 3.4 | 0.47 |
Chronic Kidney Disease | 2.8 | 1 | 1.8 |
Chronic Lyme | 0.8 | -0.8 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 1.1 | 1.18 |
Chronic Urticaria (Hives) | 1.7 | 1.2 | 0.42 |
Coagulation / Micro clot triggering bacteria | 1.9 | 1.1 | 0.73 |
Cognitive Function | 1.9 | 1.3 | 0.46 |
Colorectal Cancer | 6.5 | 2.2 | 1.95 |
Constipation | 1.8 | 0.5 | 2.6 |
Coronary artery disease | 2.7 | 2.2 | 0.23 |
COVID-19 | 7.1 | 8.5 | -0.2 |
Crohn's Disease | 7.1 | 2.9 | 1.45 |
Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
cystic fibrosis | 1.2 | 0.8 | 0.5 |
d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
deep vein thrombosis | 2.9 | 1.4 | 1.07 |
Denture Wearers Oral Shifts | 0.9 | 0.9 | |
Depression | 9.6 | 4.9 | 0.96 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 1.7 | 1.7 | 0 |
Endometriosis | 2.5 | 2 | 0.25 |
Eosinophilic Esophagitis | 0.3 | -0.3 | |
Epilepsy | 3 | 1 | 2 |
erectile dysfunction | 2.3 | 2.3 | |
Fibromyalgia | 2.3 | 1.7 | 0.35 |
Functional constipation / chronic idiopathic constipation | 5.1 | 3.9 | 0.31 |
gallstone disease (gsd) | 3.3 | 0.5 | 5.6 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.3 | 3 |
Generalized anxiety disorder | 2.9 | 1.6 | 0.81 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 2.1 | 0.8 | 1.63 |
Graves' disease | 1 | 1.7 | -0.7 |
Gulf War Syndrome | 0.8 | 1.2 | -0.5 |
Halitosis | 0.6 | 0.3 | 1 |
Hashimoto's thyroiditis | 1.7 | 0.3 | 4.67 |
Heart Failure | 3.6 | 1 | 2.6 |
hemorrhagic stroke | 0.4 | 0.4 | |
Hidradenitis Suppurativa | 0.6 | 0.6 | |
High Histamine/low DAO | 1.9 | 0.3 | 5.33 |
hypercholesterolemia (High Cholesterol) | 1.1 | 1.1 | |
hyperglycemia | 1.8 | 0.7 | 1.57 |
hypertension (High Blood Pressure | 2.2 | 3.8 | -0.73 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 2.7 | 0.6 | 3.5 |
IgA nephropathy (IgAN) | 1.6 | 3.7 | -1.31 |
Inflammatory Bowel Disease | 8.8 | 5.1 | 0.73 |
Insomnia | 1.5 | 1.7 | -0.13 |
Intelligence | 2 | 0.6 | 2.33 |
Intracranial aneurysms | 1 | 0.3 | 2.33 |
Irritable Bowel Syndrome | 5.2 | 4.1 | 0.27 |
ischemic stroke | 1.9 | 1.7 | 0.12 |
Liver Cirrhosis | 6.2 | 2.5 | 1.48 |
Long COVID | 6.1 | 3.1 | 0.97 |
Low bone mineral density | 0.8 | -0.8 | |
Lung Cancer | 1.2 | 0.3 | 3 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
ME/CFS with IBS | 1.1 | 0.3 | 2.67 |
ME/CFS without IBS | 2 | 0.9 | 1.22 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 0.9 | 0.5 | 0.8 |
Metabolic Syndrome | 5.9 | 5 | 0.18 |
Mood Disorders | 8.9 | 4.6 | 0.93 |
multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
Multiple Sclerosis | 5.1 | 4.9 | 0.04 |
Multiple system atrophy (MSA) | 1.2 | 0.3 | 3 |
myasthenia gravis | 0.9 | 0.7 | 0.29 |
neuropathic pain | 0.3 | 2.5 | -7.33 |
Neuropathy (all types) | 0.6 | 2.2 | -2.67 |
neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.9 | 1.9 | 1.58 |
NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
Obesity | 7.4 | 5.3 | 0.4 |
obsessive-compulsive disorder | 4.6 | 2.6 | 0.77 |
Osteoarthritis | 3.2 | 0.9 | 2.56 |
Osteoporosis | 2.2 | 0.6 | 2.67 |
pancreatic cancer | 0.6 | 0.3 | 1 |
Parkinson's Disease | 5 | 5.1 | -0.02 |
Polycystic ovary syndrome | 5.6 | 1.9 | 1.95 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 0.4 | -0.4 | |
primary biliary cholangitis | 0.3 | 1.1 | -2.67 |
Primary sclerosing cholangitis | 1.8 | 2.4 | -0.33 |
Psoriasis | 2 | 2.9 | -0.45 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.3 | 2.4 | 0.79 |
Rosacea | 0.3 | 0.7 | -1.33 |
Schizophrenia | 3.6 | 2.1 | 0.71 |
scoliosis | 0.9 | 0.3 | 2 |
sensorineural hearing loss | 0.5 | 0.5 | |
Sjögren syndrome | 2.2 | 1.6 | 0.38 |
Sleep Apnea | 0.6 | 1.7 | -1.83 |
Slow gastric motility / Gastroparesis | 1.2 | 1.2 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
Stress / posttraumatic stress disorder | 2.1 | 2.2 | -0.05 |
Systemic Lupus Erythematosus | 3.9 | 1.4 | 1.79 |
Tic Disorder | 1.5 | 0.6 | 1.5 |
Tourette syndrome | 0.3 | 0.3 | 0 |
Type 1 Diabetes | 3.8 | 2.2 | 0.73 |
Type 2 Diabetes | 7.5 | 5.4 | 0.39 |
Ulcerative colitis | 4.8 | 6.5 | -0.35 |
Unhealthy Ageing | 3.6 | 1.7 | 1.12 |
Vitiligo | 1.9 | 0.6 | 2.17 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]